Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Bought by Cavalier Investments LLC

Cavalier Investments LLC increased its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 3.9% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 7,585 shares of the pharmaceutical company’s stock after buying an additional 288 shares during the period. Vertex Pharmaceuticals accounts for about 1.0% of Cavalier Investments LLC’s portfolio, making the stock its 20th biggest position. Cavalier Investments LLC’s holdings in Vertex Pharmaceuticals were worth $3,054,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Edgewood Management LLC grew its stake in shares of Vertex Pharmaceuticals by 7,876.3% during the 3rd quarter. Edgewood Management LLC now owns 1,546,370 shares of the pharmaceutical company’s stock worth $719,186,000 after purchasing an additional 1,526,983 shares during the period. WCM Investment Management LLC acquired a new stake in shares of Vertex Pharmaceuticals during the 4th quarter worth approximately $435,899,000. Jennison Associates LLC grew its stake in shares of Vertex Pharmaceuticals by 18.1% during the 3rd quarter. Jennison Associates LLC now owns 5,550,386 shares of the pharmaceutical company’s stock worth $2,581,373,000 after purchasing an additional 851,054 shares during the period. Wellington Management Group LLP grew its stake in shares of Vertex Pharmaceuticals by 17.2% during the 3rd quarter. Wellington Management Group LLP now owns 4,798,870 shares of the pharmaceutical company’s stock worth $2,231,858,000 after purchasing an additional 704,421 shares during the period. Finally, Assenagon Asset Management S.A. grew its stake in shares of Vertex Pharmaceuticals by 169.4% during the 4th quarter. Assenagon Asset Management S.A. now owns 839,672 shares of the pharmaceutical company’s stock worth $338,136,000 after purchasing an additional 528,029 shares during the period. Institutional investors and hedge funds own 90.96% of the company’s stock.

Insider Activity

In other news, EVP Ourania Tatsis sold 310 shares of the company’s stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $459.83, for a total value of $142,547.30. Following the transaction, the executive vice president now owns 64,021 shares of the company’s stock, valued at $29,438,776.43. This represents a 0.48 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 0.20% of the company’s stock.

Analysts Set New Price Targets

VRTX has been the topic of a number of research analyst reports. Truist Financial lifted their price target on shares of Vertex Pharmaceuticals from $460.00 to $520.00 and gave the company a “buy” rating in a research note on Tuesday, February 11th. Canaccord Genuity Group upgraded shares of Vertex Pharmaceuticals from a “sell” rating to a “hold” rating and lifted their target price for the company from $408.00 to $424.00 in a research report on Tuesday, February 11th. Citigroup started coverage on shares of Vertex Pharmaceuticals in a research note on Thursday, November 14th. They set a “buy” rating and a $575.00 target price for the company. Wells Fargo & Company lowered shares of Vertex Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $460.00 price target on the stock. in a research note on Thursday, January 30th. Finally, JPMorgan Chase & Co. cut their price objective on Vertex Pharmaceuticals from $503.00 to $500.00 and set an “overweight” rating for the company in a research note on Monday, December 23rd. Eleven equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $506.70.

Vertex Pharmaceuticals Stock Performance

NASDAQ VRTX opened at $480.35 on Wednesday. The stock’s fifty day moving average is $436.55 and its two-hundred day moving average is $460.77. The firm has a market capitalization of $123.35 billion, a P/E ratio of -218.34, a price-to-earnings-growth ratio of 2.11 and a beta of 0.41. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.35 and a current ratio of 2.69. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $377.85 and a fifty-two week high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 EPS for the quarter, missing the consensus estimate of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. On average, research analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.